Author: Choi, Kang-Seuk
Title: Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines Document date: 2017_7_26
ID: vk59ghjm_17
Snippet: NDV vaccine strains have been used as virus vectors to develop antigen delivery vaccines for use in humans ( [37] , Ebola virus (EBOV) [38] , NiV [25] , human norovirus (NoV) [39] , respiratory syncytial virus (RSV) [40] , and human parainfluenza virus 3 (HPIV-3) [41] . Currently, no live attenuated vaccine is available for HIV-1. However, NDVs have been used as a vaccine vector to deliver the Env and Gag antigens of HIV [32, 34, 35] . For exampl.....
Document: NDV vaccine strains have been used as virus vectors to develop antigen delivery vaccines for use in humans ( [37] , Ebola virus (EBOV) [38] , NiV [25] , human norovirus (NoV) [39] , respiratory syncytial virus (RSV) [40] , and human parainfluenza virus 3 (HPIV-3) [41] . Currently, no live attenuated vaccine is available for HIV-1. However, NDVs have been used as a vaccine vector to deliver the Env and Gag antigens of HIV [32, 34, 35] . For example, Khattar et al. [34] developed two NDV-vectored HIV vaccines (rNDV-Gag/Env and rNDV-Env/Gag) expressing gp160 Env and p55 Gag, respectively (these genes were inserted between the P and M genes of NDV). Intranasal immunization of guinea pigs with these vaccines induced long-lasting Env-and Gag-specific humoral immune responses. They also induced a marked and efficient cellular and protective immune response in mice after challenge with vaccinia viruses expressing HIV-1 Env and Gag. These results suggest that vaccination with a single NDV vector coexpressing Env and Gag is a promising strategy that increases vaccine immunogenicity and subsequent protective efficacy against HIV.
Search related documents:
Co phrase search for related documents- antigen delivery and HIV vaccine: 1, 2, 3
- antigen delivery and humoral immune response: 1, 2
- antigen delivery and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48
- antigen delivery and intranasal immunization: 1, 2, 3, 4, 5, 6
- antigen delivery and live attenuated vaccine: 1, 2, 3, 4
- antigen delivery and NDV vector: 1, 2
- antigen delivery and promising strategy: 1
- antigen delivery and protective efficacy: 1, 2, 3, 4, 5
- antigen delivery and respiratory syncytial virus: 1, 2
- antigen delivery and RSV respiratory syncytial virus: 1
- antigen delivery and syncytial virus: 1, 2
- antigen delivery and vaccine immunogenicity: 1, 2, 3, 4, 5, 6, 7
- antigen delivery and vaccine strain: 1, 2
- antigen delivery and vaccine vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- antigen delivery and vaccinia virus: 1, 2, 3, 4
- antigen delivery and virus vector: 1, 2, 3, 4, 5, 6, 7, 8
- antigen delivery vaccine and Ebola virus: 1
- antigen delivery vaccine and humoral immune response: 1
- antigen delivery vaccine and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9
Co phrase search for related documents, hyperlinks ordered by date